Comparison of Alectinib/Crizotinib Data in First-Line Therapy in Patients with Anaplastic LymphomakinasePositive Nonsmall Cell Lung Carcinoma with Poor Prognostic Features for Alectinib

Comparison of Alectinib/Crizotinib Data in First-Line Therapy in Patients with Anaplastic LymphomakinasePositive Nonsmall Cell Lung Carcinoma with Poor Prognostic Features for Alectinib

Bibliographic Details
Main Authors: Nuran Katgı, Pınar Çimen, Murat Akyol, Pınar Gürsoy, Nurşin Agüloğlu
Format: Article
Language:English
Published: AVES 2023-07-01
Series:Thoracic Research and Practice
Online Access:https://thoracrespract.org/en/comparison-of-alectinib-crizotinib-data-in-first-line-therapy-in-patients-with-anaplastic-lymphomakinasepositive-nonsmall-cell-lung-carcinoma-with-poor-prognostic-features-for-alectinib-132216

Internet

https://thoracrespract.org/en/comparison-of-alectinib-crizotinib-data-in-first-line-therapy-in-patients-with-anaplastic-lymphomakinasepositive-nonsmall-cell-lung-carcinoma-with-poor-prognostic-features-for-alectinib-132216

Similar Items